Back to Research Home
CONConcentra Group Holdings Parent, Inc.
Health Care · Medical Specialities · Mid
$39.25−1.80%
As of 23 Oct 2026Mkt cap $4.3B
Stage 13
AVOID
Fundamentals
39.2/75
Technical
4.9/15
Independent
44.1/90
GCAE viewFundamental /75 is below the Stage 13 acceptable-business floor
Price
- 1M
- +13.4%
- 3M
- +23.1%
- 6M
- +72.0%
- 1Y
- +89.5%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- —
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- 18.8x
- FCF yield
- 5.3%
Quality
- ROIC
- 14.9%
- Operating margin
- 15.6%
- FCF margin
- 9.1%
- Current ratio
- 1.1x
Growth
- Revenue growth
- +13.9%Latest FY YoY
- Revenue CAGR
- +7.9%
- EPS CAGR
- −6.7%
- FCF CAGR
- −4.8%
Capital
- Share-count trend
- +11.0%3Y annualised
- Net debt
- $1.5B5.3x OCF
Annual trend
- CAGR 2022–2025
- +7.9%
- Latest · 2025
- $2B
- YoY
- +13.9%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
Fundamental /75 is below the Stage 13 acceptable-business floor
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-11-05
More details & evidence
Production decision
- Stage 13
- AVOID
- Technical state
- extended
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded